Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 401–500 of 1,004
Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Hirschberg, A. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad590 · Cited by 47
Anti‐Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
Sathyapalan, T., Al‐Qaissi, A., Kilpatrick, E. S., Dargham, S. R., & Atkin, S. L. (2017) · Clinical Endocrinology · doi:10.1111/cen.13517 · Cited by 46
de Medeiros, S. F., de Medeiros, M. A. S., Ormond, C. M., Barbosa, J. S., & Yamamoto, M. M. W. (2017) · Gynecologic and Obstetric Investigation · doi:10.1159/000485619 · Cited by 46
Arancio, W., Amato, M. C., Magliozzo, M., Pizzolanti, G., Vesco, R., & Giordano, C. S. D. S. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1428299 · Cited by 46
“PCOS is a complex endocrinopathy with poorly understood etiology [2] characterized by variable features, which may include: biochemical and clinical hyperandrogenism, menstrual and ovulatory dysfunctions and polycystic ovaries with exclusion of other androgenic, pituitary or adrenal causes [2].”
BackgroundLi, A., Lu, Z., Jiajia, J., Yang, N., Ying, L., Lingbo, C., Yugui, C., Feiyang, D., Han, X., Jiayin, L., et al. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20170136 · Cited by 47
Polycystic ovary syndrome in adult women
Ortiz-Flores, A. E., Luque-Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.02.019 · Cited by 37
Racial and ethnic differences in the metabolic response of polycystic ovary syndrome
Ezeh, U. I., Chen, Y.-D. I., & Azziz, R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14193 · Cited by 46
The role of miRNAs in polycystic ovary syndrome with insulin resistance
Luo, Y., Cui, C., Han, X., Wang, Q., & Zhang, C. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-02019-7 · Cited by 46
“PCOS is associated with various diseases, including anovulatory infertility [3] and metabolic disorders such as metabolic syndrome, type 2 diabetes, and cardiovascular disease in women [4, 5].”
BackgroundMallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
What do we know about metabolic syndrome in adolescents with PCOS?
Cırık, D. A., & Dilbaz, B. (2014) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2014.95776 · Cited by 47
“Because central obesity is associated with hyperandrogenism and cardiovascular diseases, the Endocrine Society also recommends screening adolescents with PCOS for central obesity by body mass index (BMI) and waist circumference measurements (4).”
BackgroundMethodInfluentialNutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users
Luciano‐Mateo, F., Hernández‐Aguilera, A., Cabré, N., Camps, J., Fernández‐Arroyo, S., López‐Miranda, J., Menéndez, J. A., & Joven, J. (2017) · Nutrients · doi:10.3390/nu9020121 · Cited by 44
Zhang, L., Fang, X., Li, L., Liu, R., Zhang, C., Liu, H., Tan, M., & Yang, G. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0902-4 · Cited by 45
A Review of the Impact of Bariatric Surgery in Women With Polycystic Ovary Syndrome
Lee, R. H., Mathew, C. J., Jose, M. T., Elshaikh, A. O., Shah, L., & Cancarevic, I. (2020) · Cureus · doi:10.7759/cureus.10811 · Cited by 45
“Per recommendation by the Endocrine Society, the diagnosis of PCOS should be based on the 2003 Rotterdam criteria [6].”
MethodBarrea, L., Donnarumma, M., Cacciapuoti, S., Muscogiuri, G., de Gregorio, L., Blasio, C., Savastano, S., Colao, A., & Fabbrocini, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02826-1 · Cited by 45
“Endocrine disorders that could affect body composition or nutritional status, such as hyperandrogenism and/or biochemical hyperandrogenaemia, oligomenorrhea due to polycystic ovarian syndrome or secondary aetiologies according to the Endocrine Society, including thyroid dysfunction, Cushing’s syndrome, adrenal disorde…”
BackgroundRosenfield, R. L., Ehrmann, D. A., & Littlejohn, E. E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4290 · Cited by 42
“While adolescent hirsutism alone or oligo-amenorrhea alone are not highly predictive of adult PCOS, in this series the combination of the two, which was present in 75% of our FOH cases and meets standard criteria for PCOS (ie, otherwise unexplained evidence of hyperandrogenic anovulation) (5), was highly predictive of…”
BackgroundResultSelf-citationAyesh, H., Nasser, S. A., Ferdinand, K. C., & Leon, B. G. C. (2025) · Circulation Research · doi:10.1161/circresaha.124.325535 · Cited by 46
Sørensen, A. E., Udesen, P. B., Maciag, G. J., Geiger, J., Saliani, N., Januszewski, A. S., Jiang, G., Ronald, C. W., Hardikar, A. A., Wissing, M. L., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00242 · Cited by 44
Bandariyan, E., Mogheiseh, A., & Ahmadi, A. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03229-x · Cited by 44
Are young adult women with polycystic ovary syndrome slipping through the healthcare cracks?
Dokras, A., & Witchel, S. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4190 · Cited by 43
Genetics of Polycystic Ovary Syndrome
Welt, C. K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.006 · Cited by 43
Self-citationThe relationship between polycystic ovary syndrome and infertility: a bibliometric analysis
Zhuang, S., Jing, C., Yu, L., Ji, L., Liu, W., & Hu, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-714 · Cited by 43
Kim, J. Y., Tfayli, H. M., Michaliszyn, S. F., Lee, S., & Arslanian, S. A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.02.004 · Cited by 43
“The diagnosis of PCOS was made based on the presence of clinical signs and symptoms of hyperandrogenism and/or biochemical hyperandrogenemia, oligomenorrhea, and the exclusion of secondary etiologies as per the Endocrine Society Clinical Practice Guidelines and previous publications (7, 12, 13, 16).”
BackgroundMethodSelf-citationPolycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies
Jacewicz‐Święcka, M., & Kowalska, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3054 · Cited by 38
“2 of 26 JACEWICZ‐ŚWIĘCKA AND KOWALSKA It is widely recognized that women with PCOS have greater tendency to obesity(14) and accumulation of central or visceral fat,(15) compared with weight‐matched healthy women, that is associated with higher frequency and degree of hyperinsulinaemia, IR, and increased metabolic risk…”
BackgroundMethodInfluentialJia, C., Wang, S., Yin, C., Liu, L., Zhou, L., & Ma, Y. (2020) · Gene · doi:10.1016/j.gene.2020.144591 · Cited by 43
Depressive and Anxiety Symptom Assessment in Adults with Polycystic Ovarian Syndrome
Almeshari, W. K., Alsubaie, A. K., Alanazi, R. I., Almalki, Y., Masud, N., & Mahmoud, S. H. (2021) · Depression Research and Treatment · doi:10.1155/2021/6652133 · Cited by 44
“Its diagnostic criteria include chronic oligo or anovulation, defined as irregular or none occurring menstrual cycles, presence of ovarian cysts on ultrasound examination, and high levels of androgen hormones [4].”
BackgroundKristensen, S. G., Kumar, A., Mamsen, L. S., Kalra, B., Pors, S. E., Bøtkjær, J. A., Macklon, K. T., Fedder, J., Ernst, E., Hardy, K., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac272 · Cited by 44
Quercetin and polycystic ovary syndrome
Ma, C., Xiang, Q., Song, G., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006678 · Cited by 44
“HA is an independent risk factor for long-term health outcomes associated with PCOS (Legro et al., 2013), and the incidence of HA in PCOS patients is as high as 60%–80% (Ye et al.”
BackgroundManagement of Polycystic Ovary Syndrome in India
Malik, S., Jain, K., Talwar, P., Prasad, S., Dhorepatil, B., Devi, G., Khurana, A., Bhatia, V., Chandiok, N., Kriplani, A., et al. (2014) · Fertility Science and Research · doi:10.4103/2394-4285.146798 · Cited by 43
“…ovary syndrome; NIH: National Institute of Health; AE-PCOS: Androgen excess-polycystic ovary syndrome; PCO: Polycystic ovary, Source: Adapted from Legro et al. 2013 Fertility Science and Research / Jan-Jun 2014 / Vol 1 | Issue 126 The diagnostic criteria proposed for diagnosis of PCOS are…”
BackgroundPolycystic ovary syndrome: chemical pharmacotherapy
Rocca, M. L., Venturella, R., Mocciaro, R., Cello, A. D., Sacchinelli, A., Russo, V. M., Trapasso, S., Zullo, F., & Morelli, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047344 · Cited by 43
“2 Antiandrogens Antiandrogens are the most effective drugs currently available for the hirsutism management; they should be applied for moderate/severe hirsutism; moreover, they could be administered after 6 months of COCs or after COCs failure [11,21,63].”
BackgroundInfluentialChang, A. Y., Oshiro, J., Ayers, C. R., & Auchus, R. J. (2015) · Clinical Endocrinology · doi:10.1111/cen.12986 · Cited by 43
Are there new insights for the definition of PCOS?
Baracat, E. C., Baracat, M. C. P., & Soares, J. M. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2121387 · Cited by 43
Menstrual suppression for adolescents
Altshuler, A. L., & Hillard, P. J. A. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000098 · Cited by 42
“Unautho Health | Lippincott Williams & Wilkins (c) Endometriosis [9 & ,10] (d) Heavy menstrual bleeding [7,11 && ] (i) Anemia due to heavy menstrual bleeding (e) Irregular bleeding/anovulation (i) Polycystic ovary syndrome (PCOS) [12] (f) Preprocedure (i) Obstructing utero-vaginal anomalies pending definitive surgery…”
BackgroundLiu, Z., Hao, C., Huang, X. Y., Zhang, N., Bao, H., & Qu, Q. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.999763 · Cited by 42
“This disorder accounts for 75% of the anovulatory infertility [2] and is highly associated with obesity, insulin resistance (IR) and dyslipidemia, along with an increased risk of diabetes and cardiovascular events.”
BackgroundAn implementation of convolutional neural network on PCO classification based on ultrasound image
Cahyono, B., Adiwijaya, A., Mubarok, M. S., & Wisesty, U. N. (2017) · doi:10.1109/icoict.2017.8074702 · Cited by 42
“However, PCOS can also affecting woman as young as 11 years old [4].”
BackgroundCree‐Green, M., Carreau, A., Rahat, H., Garcia‐Reyes, Y., Bergman, B. C., Pyle, L., & Nadeau, K. J. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00532.2018 · Cited by 43
Ara, M. M. I. (2022) · International Journal of Current Research in Physiology and Pharmacology (IJCRPP) · doi:10.5281/zenodo.7384710 · Cited by 42
Polycystic Ovary Syndrome (PCOS) and Fertility
Barbosa, G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61008 · Cited by 42
“The diagnosis of PCOS is very important, because it identifies the metabolic risks, the potential cardiovascular risk and mainly because such a diagnosis interferes directly with the fertility status of these patients [38].”
BackgroundGreenwood, E. A., Pasch, L. A., Shinkai, K., Cedars, M. I., & Huddleston, H. G. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.10.004 · Cited by 36
Gao, T., Wu, L., Chang, F., & Cao, G. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0318 · Cited by 41
“POLYCYSTIC OVARY SYNDROME (PCOS) remains one of the most common endocrinopathies [1].”
Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome
Hamilton, K. P., Zelig, R., Parker, A. R., & Haggag, A. (2019) · Current Developments in Nutrition · doi:10.1093/cdn/nzz108 · Cited by 41
Alternative splicing of DENND1A, a PCOS candidate gene, generates variant 2
Tee, M. K., Speek, M., Legeza, B., Modi, B., Teves, M. E., McAllister, J. M., Strauss, J. F., & Miller, W. L. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.011 · Cited by 36
“PCOS is associated with hyperandrogenemia, hyperandrogenism, anovulation, infertility, and multiple small subcortical ovarian follicular “cysts” (2,3).”
BackgroundHeshmati, J., Omani-Samani, R., Vesali, S., Maroufizadeh, S., Rezaeinejad, M., Razavi, M., & Sepidarkish, M. (2018) · Hormone and Metabolic Research · doi:10.1055/s-0044-101835 · Cited by 38
“Several factors are involved in the incidence of this syndrome, but these are unknown and attributed to genetics [5].”
BackgroundPolycystic ovary syndrome and periodontal disease: Underlying links- A review
Tanguturi, S. C., & Nagarakanti, S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_577_17 · Cited by 41
“[20] It usually affects women in their reproductive years.[21] Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, which negatively affects various health systems.”
BackgroundDiagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?
Andersen, M., & Glintborg, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0237 · Cited by 36
Saeed, N. A.-H. A. A. H., Hamzah, I. H., & Al-Gharrawi, S. A. R. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4453-3 · Cited by 41
Greenwood, E. A., Pasch, L. A., Cedars, M. I., & Huddleston, H. G. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.01.016 · Cited by 41
“P olycystic ovary syndrome (PCOS) (1) is a common endocrinopathy with multisystem consequences (2).”
BackgroundInfluentialLyu, X., Lyu, T., Wang, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6616693 · Cited by 33
Xia, Q., Xie, L., Wu, Q., Cong, J., Ma, H., Li, J., Cai, W.-Y., & Wu, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13024 · Cited by 41
“Participants were between 20 and 40 years, fulfilled the modified Rotterdam diagnostic criteria for PCOS: oligomenorrhea or amenorrhea, together with clinical or biochemical hyperandrogenism and/or polycystic ovaries [9,20].”
MethodSun, L., Cheng, J., Jin, L., Bi, Y., Feng, W., Li, P., Shen, S., & Zhu, D. (2016) · Reproductive Sciences · doi:10.1177/1933719116635278 · Cited by 41
“The syndrome presents with elevated levels of androgen secretion, ovulatory dysfunction, or polycystic ovaries.(2) In addition to these characteristics, metabolic disturbances such as insulin resistance (IR) and obesity have also been linked to PCOS.”
BackgroundPsychological aspects of hyperandrogenic states in late adolescent and young women
Guidi, J., Gambineri, A., Zanotti, L., Fanelli, F., Fava, G. A., & Pasquali, R. (2015) · Clinical Endocrinology · doi:10.1111/cen.12783 · Cited by 40
Self-citationPark, K., Wei, J., Minissian, M., Bairey Merz, C. N., & Pepine, C. J. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6597-2 · Cited by 40
“from 6 to 8 % of women overall [70].”
BackgroundPCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Health benefits of combined oral contraceptives – a narrative review
Bennink, H. J. T. C., van Gennip, F. A. M., Gerrits, M., Egberts, J. F. M., Gemzell‐Danielsson, K., & Kallner, H. K. (2024) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2024.2317295 · Cited by 40
Begum, G. S., Almashaikhi, N. A. T., AlBalushi, M. H., Alsalehi, H. M., Alazawi, R. S., Goud, M., & Dube, R. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21091165 · Cited by 42
“Our study findings align with a prevalence rate of 3.86% for PCOS among tenth-grade schoolgirls in the Guangzhou area, as determined by the NIH criteria [32].”
BackgroundInfluentialTroisi, J., Cinque, C., Giugliano, L., Symes, S. J. K., Richards, S. M., Adair, D. C., Cavallo, P., Sarno, L., Scala, G., Caiazza, M., et al. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0500-x · Cited by 40
Postmenopausal Hyperandrogenism
Zaman, A., & Rothman, M. S. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.12.002 · Cited by 40
Ma, L., Cao, Y., Ma, Y., & Zhai, J. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1897096 · Cited by 40
Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women
Li, W., Hu, H., Zou, G., Ma, Z., Liu, J., & Li, F. (2021) · Medicine · doi:10.1097/md.0000000000026049 · Cited by 40
Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
Doycheva, I., & Ehrmann, D. A. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.020 · Cited by 40
Self-citationKaur, R., Kumar, R., & Gupta, M. (2022) · Computers & Electrical Engineering · doi:10.1016/j.compeleceng.2022.108298 · Cited by 41
COVID-19 vaccination and changes in the menstrual cycle among vaccinated persons
Farland, L. V., Khan, S. R., Shilen, A., Heslin, K. M., Ishimwe, P., Allen, A. M., Herbst‐Kralovetz, M. M., Mahnert, N. D., Pogreba-Brown, K., Ernst, K. C., et al. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.12.023 · Cited by 41
“Days from the second vaccine dose to the completion of the first survey where they reported a change 112 (79) 91 [6-359]”
BackgroundMendoza, N., Simoncini, T., & Genazzani, A. D. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.943725 · Cited by 38
Associations between vitamin D levels and polycystic ovary syndrome phenotypes
Davis, E. M., Peck, J. D., Hansen, K. R., Neas, B. R., & Craig, L. B. (2019) · Minerva Endocrinologica · doi:10.23736/s0391-1977.18.02824-9 · Cited by 39
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
“PCOS is a diagnosis of exclusion that can be determined by the National Institute of Health, the Androgen Society, or the Rotterdam criteria [3].”
Hadidi, M., Karimabadi, K., Ghanbari, E., Rezakhani, L., & Khazaei, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1269266 · Cited by 40
“Diagnosing PCOS in adolescents, however, can be challenging because of the signi fi cant overlap of its symptoms with normal changes during puberty, making accurate diagnosis dif fi cult most of the time (17, 18, 21).”
BackgroundMeneghini, C., Bianco, C., Galanti, F., Tamburelli, V., Lago, A. D., Licata, E., Gallo, M., Fabiani, C., Corno, R., Miriello, D., et al. (2023) · Nutrients · doi:10.3390/nu15204444 · Cited by 39
“Metformin is efficient but has gastroenteric side effects and is considered a US Food and Drug Administration (FDA) pregnancy category B drug [7,27].”
BackgroundWilliams, N. I., Souza, M. J. D., Misra, M. D. D. S. K., Nattiv, A., Joy, E. A., Barrack, M. T., Ricker, E. A., Gorrell, S., Koltun, K. J., O’Donnell, E., et al. (2025) · Sports Medicine · doi:10.1007/s40279-025-02332-0 · Cited by 43
Wang, Y., Fu, X., Xu, J., Wang, Q., & Kuang, H. (2016) · Scientific Reports · doi:10.1038/srep28089 · Cited by 35
Tan, M. H., Alquraini, H., Mizokami‐Stout, K., & MacEachern, M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.008 · Cited by 40
Bakeer, E. M., Radwan, R. A., El-Mandoury, A. A.-A., Rahman, A. A. A. E., Gad, M. Z., & Maksoud, S. A. (2018) · Journal of Medical Biochemistry · doi:10.1515/jomb-2017-0068 · Cited by 39
“However, these results alone are not adequate to establish a causal relationship between high BMI and PCOS diagnosis (17).”
BackgroundCarmina, E., Nasrallah, M., Guastella, E., & Løbo, R. A. (2019) · Clinical Endocrinology · doi:10.1111/cen.14063 · Cited by 39
Kristensen, S. G., Kumar, A., Kalra, B., Pors, S. E., Bøtkjær, J. A., Mamsen, L. S., Colmorn, L. B., Fedder, J., Ernst, E., Owens, L. A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01094 · Cited by 39
Nunes, R. D. L., dos Santos, Í. K., Cobucci, R. N., Pichini, G. S., Soares, G. M., Maranhão, T. M. D. O., & Dantas, P. M. S. (2019) · Medicine · doi:10.1097/md.0000000000018323 · Cited by 40
“In this sense, the guidelines recommend as a form of no pharmacologic treatment for women with PCOS, the insertion of exercises and a diet with caloric restriction as crucial elements, in order to reduce the consequences of the symptoms of PCOS on the health and consequently on the quality of life of women.([11]) Life…”
BackgroundLi, L., Zhang, J., Zeng, J., Liao, B., Peng, X., Li, T., Li, J., Tan, Q., Li, X., Yang, Y., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4522 · Cited by 39
Dietary Approaches to Women’s Sexual and Reproductive Health
Kudesia, R., Alexander, M., Gulati, M., Kennard, A., & Tollefson, M. (2021) · American Journal of Lifestyle Medicine · doi:10.1177/15598276211007113 · Cited by 39
Biomedical features of flaxseed against different pathologic situations: A narrative review.
Ebrahimi, B., Nazmara, Z., Hassanzadeh, N., Yarahmadi, A., Ghaffari, N., Hassani, F., Liaghat, A., Noori, L., & Hasanzadeh, G. (2021) · PubMed Central · doi:10.22038/ijbms.2021.49821.11378 · Cited by 39
“Any substances that can decrease androgen levels will be beneficial in androgen-dependent disorders such as PCOS.”
BackgroundInfluentialEthirajulu, A., Alkasabera, A., Onyali, C. B., Anim-Koranteng, C., Shah, H. E., Bhawnani, N., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.18013 · Cited by 39
“The diagnostic criteria include the following: chronic oligo or anovulation in women where serum FSH and LH should be tested, presence of numerous cysts in the ovaries in ultrasound examination, presence of elevated androgen levels [20].”
BackgroundEzeh, U. I., Pisarska, M. D., & Azziz, R. (2022) · Human Reproduction · doi:10.1093/humrep/deac001 · Cited by 40
Metformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0311-1 · Cited by 39
Self-citationImpact of hypocaloric dietary intervention on ovulation in obese women with PCOS
Jarrett, B. Y., & Lujan, M. E. (2017) · Reproduction · doi:10.1530/rep-16-0385 · Cited by 39
Szczuko, M., Zapałowska-Chwyć, M., Drozd, A., Maciejewska, D., Starczewski, A., & Stachowska, E. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.09.001 · Cited by 39
Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome
Boumosleh, J. M., Grundy, S. M., Phan, J., Neeland, I. J., Chang, A. Y., & Vega, G. L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00323 · Cited by 39
Ding, T., Hardiman, P. J., Petersen, I., & Baio, G. (2018) · Human Reproduction · doi:10.1093/humrep/dey093 · Cited by 38
Paganini, C., Peterson, G., Stavropoulos, V., & Krug, I. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666171204151209 · Cited by 35
“Another therapeutic approach aimed to establish ovulsatory cycles involves the administration of Insulin-Sensitizing Drugs (metformin) in order to reduce the hyperandrogenemia, restore of ovulatory function and increase of pregnancy rates [85, 86].”
BackgroundIntegrated Model of Care for Polycystic Ovary Syndrome
Tay, C., Moran, L., Wijeyaratne, C., Redman, L., Norman, R., Teede, H., & Joham, A. (2018) · Seminars in Reproductive Medicine · doi:10.1055/s-0038-1667310 · Cited by 29
Ortiz-Flores, A. E., Luque‐Ramírez, M., Fernández‐Durán, E., Álvarez‐Blasco, F., & Escobar-Morreale, H. F. (2019) · Metabolism · doi:10.1016/j.metabol.2019.01.015 · Cited by 38
Ovarian drilling in polycystic ovary syndrome: Long term pregnancy rate
Debras, É., Fernandez, H., Neveu, M.-E., Deffieux, X., & Capmas, P. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology X · doi:10.1016/j.eurox.2019.100093 · Cited by 38
“PCOS is defined using the Rotterdam criteria [2,3].”
MethodRosenfield, R. L. (2020) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2020.06.017 · Cited by 39
Koutaki, D., Michos, A. G., Bacopoulou, F., & Charmandari, E. (2021) · Nutrients · doi:10.3390/nu13072459 · Cited by 38
Huang, C., Lin, B., Yuan, Y., Li, K., Xu, B., Zhang, P., Wei, X., Wang, W., Liu, W., Deng, Y., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029020 · Cited by 38
Wen, Q., Fang, S., Liang, Y., Tian, Y., Chen, Y., Yuan, J., & Qiu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156521 · Cited by 39
“Current literature indicates that metformin and GLP-1RAs are often used in the treatment of PCOS due to the improvement of fat distribution and reducing abdominal circumference (36, 37).”
BackgroundMaslyanskaya, S., Talib, H. J., Northridge, J. L., Jacobs, A. M., Coble, C., & Coupey, S. M. (2016) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2016.11.009 · Cited by 38
Traditional Persian Medicine and management of metabolic dysfunction in polycystic ovary syndrome
Hosseinkhani, A., Asadi, N., Pasalar, M., & Zarshenas, M. M. (2017) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2017.04.006 · Cited by 38
Yi, D. Y., Kim, S. C., Lee, J. H., Lee, E. H., Kim, J. Y., Kim, Y. J., Kang, K. S., Hong, J., Shim, J. O., Lee, Y. M., et al. (2019) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2019.22.1.1 · Cited by 38
“lists the suggested obesity-related comorbidities and their corresponding screening tests [17-22].”
BackgroundKulkarni, R., Teves, M. E., Han, A. X., McAllister, J. M., & Strauss, J. F. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00169 · Cited by 37
Shah, A., Dodson, W. C., Kris‐Etherton, P. M., Kunselman, A. R., Stetter, C., Gnatuk, C. L., Estes, S. J., Allison, K. C., Sarwer, D. B., Sluss, P. M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa682 · Cited by 37
Self-citationNonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review
von Hafe, M., Borges‐Canha, M., Vale, C., Leite, A. R., Neves, J. S., Carvalho, D. M., & Leite-Moreira, A. F. (2022) · Metabolites · doi:10.3390/metabo12040298 · Cited by 37
The Effect on Inflammation of Adherence to the Mediterranean Diet in Polycystic Ovary Syndrome
Dazıroğlu, M. E. Ç., & Tek, N. A. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00451-6 · Cited by 37
Novel strategies in the management of polycystic ovary syndrome.
Spritzer, P. M., Motta, A. B., Sir‐Petermann, T., & Diamanti‐Kandarakis, E. (2015) · PubMed · Cited by 37
Cao, Z. T., Botelho, J. C., Rej, R., & Vesper, H. W. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.03.010 · Cited by 37
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.